Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized AER101 for Pre-Operative NSCLC
NCT07631299Phase 1Not yet recruiting
- Sponsor
- University of Oklahoma
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 2-deoxy-d-glucose in non-small cell lung cancer (NSCLC), sponsored by University of Oklahoma. Primary endpoint: Positron Emission Tomography Standardized Uptake Value Maximum at 14 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
2-deoxy-d-glucose
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07631299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07631299.